Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

PTSD: Current Therapies

Childhood abuse, motor vehicle accidents, assault, and other psychological traumas and stressors represent a major public health problem in our society today. Psychological trauma, defined as threat to life or...
CME credit is no longer available for this conference.

Course Authors

J. Douglas Bremner, M.D.

Dr. Bremner is Professor of Psychiatry and Radiology at the Emory University School of Medicine, Atlanta, Georgia, and author of You Can’t Just Snap Out Of It: The Real Path To Recovery From Psychological Trauma: Introducing the START NOW Program.

Within the past 12 months, Dr. Bremner has no conflicts of interest relevant to this activity.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • List the effects of stressors such as combat or childhood abuse on the brain and cognition, and the implications for health, public policy, rehabilitation and psychiatric treatment;

  • Describe studies that show smaller volume of the hippocampus in posttraumatic stress disorder with associated cognitive memory deficits and explain theories behind these findings and effects of treatment on memory and the hippocampus;

  • Discuss how dysfunction of medial prefrontal cortex and increased function in the amygdala may contribute to symptoms of stress-related disorders like PTSD, and the effects of treatment on these brain areas;

  • Apply treatments for stress-related disorders, including PTSD and depression, that have been shown to have efficacy for these conditions.



The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like

Emerging Research on the Use of Psychedelics in the Treatment of Mental Illness

In the last 30 years, revived interest in the application of psychedelic compounds in psychiatry has created a huge body of scientific knowledge on the pharmacological and therapeutic action of these compounds.
Authors: Danilo De Gregorio, PharmD, Ph.D.
Estimated Time: 1 Hour

The Impact of COVID-19 on Mental Health

The coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (W.H.O.) on March 11, 2020. China was the first country that identified the novel coronavirus as the cause of the pandemic. Globally, as of May 25, 2020, the number of confirmed cases was 5,525,299, the number of deaths was 347,110 and the number of recovered cases was 2,316,127. The challenges of COVID-19 pandemic include the following issues: modified lifestyle due to lockdown and
Authors: Roger Ho M.D., F.R.C.Psych., F.R.C.P.C., and Cyrus Ho M.B.B.S., M.R.C.Psych.
Estimated Time: 1 Hour

Molecular Mechanisms of Cognitive Deficits in Schizophrenia

Schizophrenia is a severe mental disorder characterized by three main symptom domains: positive, negative and cognitive. While positive symptoms such as hallucinations and delusions are largely responsive to antipsychotic medication, negative symptoms like anhedonia, and cognitive symptoms such as memory and attentional deficits, constitute a major unmet therapeutic need. Cognitive symptoms, in particular, have been the focus of substantial on-going clinical and preclinical research as cognitive impairment is highly predictive of long-term functional outcome in patients.
Authors: Sarah Canetta, Ph.D., and Christoph Kellendonk, Ph.D.
Estimated Time: 1 Hour

Current and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis

This presentation may include discussion of commercial products and services. Dr. Miller will discuss unapproved therapies for MS including daclizumab, ocrelizumab, sphingosine-1-phosphate receptor molecules and ofatumumab. The modern era of disease modifying therapy (DMT) in multiple sclerosis (MS) began in 1993 with the introduction of interferon beta-1b for the treatment of relapsing-remitting multiple sclerosis (RMMS). Since then, the U.S. Food and Drug Administration (FDA) has approved eight new unique therapeutic agents (actually nine products). In other parts
Authors: Aaron Miller, M.D..
Estimated Time: 1 Hour

Glial Cells

Astrocyte: Astrocytes are a type of non-neuronal cell in the central nervous system that exhibit a wide variety of cellular properties and shapes. These cells are involved in a broad range of functions in disease and normal brain function. Microglia: Microglia are the immune system cells of the central nervous system, but they also help remodel synapses in response to neural activity. Oligodendrocyte: Oligodendrocytes form the multi-laminar myelin electrical insulation on axons in the
Authors: R. Douglas Fields, Ph.D.
Estimated Time: 1 Hour

The Management of Major Depression During Pregnancy

Susan has a history of severe recurrent depressive episodes with debilitating panic attacks beginning at age 14. She has been tried on all currently available SSRI medications, as well as buproprion, mirtazapine and serezone. She has been successfully treated with paroxetine for the last three years and was either unable to tolerate or did not respond to the previous medication trials. She presents asking for treatment advice during pregnancy. How should her psychiatrist approach weighing the risks and
Authors: Jennifer L. Payne, M.D.
Estimated Time: 1 Hour